Halozyme to Report Third Quarter 2025 Financial and Operating Results
Halozyme (NASDAQ: HALO) will release its third quarter 2025 financial and operating results on Monday, November 3, 2025 following the close of trading.
The company will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss results. The call requires pre-registration via the provided link and a live webcast and replay will be available in the Investors section of Halozyme's website.
Halozyme (NASDAQ: HALO) rilascerà i risultati finanziari e operativi del terzo trimestre 2025 lunedì 3 novembre 2025 dopo la chiusura degli scambi.
L'azienda ospiterà una conference call lunedì 3 novembre 2025 alle 13:30 PT / 16:30 ET per discutere i risultati. La chiamata richiede la registrazione anticipata tramite il link fornito e una trasmissione in streaming dal vivo e la riproduzione saranno disponibili nella sezione Investitori del sito web di Halozyme.
Halozyme (NASDAQ: HALO) divulgará sus resultados financieros y operativos del tercer trimestre de 2025 el lunes 3 de noviembre de 2025 después del cierre de la sesión.
La empresa organizará una conferencia telefónica el lunes 3 de noviembre de 2025 a las 1:30 p.m. PT / 4:30 p.m. ET para discutir los resultados. La llamada requiere registro previo mediante el enlace proporcionado y una transmisión en vivo y la repetición estarán disponibles en la sección de Inversores del sitio web de Halozyme.
Halozyme (NASDAQ: HALO)는 2025년 3분기 재무 및 운영 결과를 2025년 11월 3일 월요일에 장 마감 후 발표합니다.
회사는 결과를 논의하기 위해 2025년 11월 3일 월요일 1:30 p.m. PT / 4:30 p.m. ET에 컨퍼런스 콜을 주최합니다. 이 전화는 제공된 링크를 통한 사전 등록이 필요하며 라이브 스트림 및 재방송은 Halozyme의 웹사이트의 투자자 섹션에서 이용할 수 있습니다.
Halozyme (NASDAQ: HALO) publiera ses résultats financiers et opérationnels du troisième trimestre 2025 le lundi 3 novembre 2025 après la clôture des échanges.
L'entreprise organisera une conférence téléphonique le lundi 3 novembre 2025 à 13h30 PT / 16h30 ET pour discuter des résultats. L'appel nécessite une préinscription via le lien fourni et une diffusion en direct et une réplique seront disponibles dans la section Investisseurs du site Web de Halozyme.
Halozyme (NASDAQ: HALO) wird seine finanziellen und operativen Ergebnisse des dritten Quartals 2025 am Montag, den 3. November 2025 nach Börsenschluss veröffentlichen.
Das Unternehmen wird am Montag, den 3. November 2025 um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Der Anruf erfordert eine Vorregistrierung über den bereitgestellten Link, und ein Live-Webcast sowie eine Wiederholung werden im Bereich Investoren der Halozyme-Website verfügbar sein.
Halozyme (NASDAQ: HALO) ستعلن عن نتائجها المالية والتشغيلية الخاصة بالربع الثالث من 2025 يوم الاثنين 3 نوفمبر 2025 بعد إغلاق التداول.
ستعقد الشركة اتصالًا هاتفيًا للمناقشة النتائج يوم الاثنين 3 نوفمبر 2025 الساعة 1:30 ظهرًا بتوقيت المحيط الهادئ / 4:30 عصرًا بتوقيت شرق الولايات المتحدة. يتطلب الاتصال تسجيلًا مسبقًا عبر الرابط المقدم، وسيكون البث الحي وإعادة البث متاحين في قسم المستثمرين بموقع Halozyme الإلكتروني.
Halozyme (NASDAQ: HALO) 将于 2025 年 11 月 3 日（星期一） 收盘后公布其 2025 年第三季度的财务与运营业绩。
公司将于 2025 年 11 月 3 日（星期一） 1:30 p.m. PT / 4:30 p.m. ET 举行电话会议以讨论结果。此通话需要通过提供的链接进行预注册，实时网络广播和回放将在 Halozyme 网站的 投资者 部分提供。
- None.
- None.
Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137280.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2025-financial-and-operating-results-302589996.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (HALO) report Q3 2025 results?
What time is the Halozyme (HALO) Q3 2025 conference call?
How can investors access the Halozyme (HALO) November 3, 2025 call?
Will there be a replay of the Halozyme (HALO) Q3 2025 conference call?
Is the Q3 2025 Halozyme (HALO) results release scheduled before or after the conference call?
What ticker should investors use to follow Halozyme ahead of the November 3, 2025 release?
